Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

The Effectiveness and Safety of Hypertonic Citrate Adenine-New (HCA-N) Solution for the Preservation of Kidney Grafts During Kidney Transplantation

17 de setembro de 2026 atualizado por: Zhongnan Hospital

A Multicenter, Randomized, Double-blind, Positive-control, Non-inferiority Clinical Trial on the Effectiveness and Safety of Hypertonic Citrate Adenine-New (HCA-N) Solution for the Preservation of Kidney Grafts During Kidney Transplantation

To verify the effectiveness and safety of the HCA-N solution in actual clinical preservation, this study intends to conduct a prospective, randomized, and positive control clinical trial. Using the classic HTK solution as a reference, the study will focus on evaluating the performance of the HCA-N solution in terms of the incidence of delayed recovery of transplant kidney function and the speed of early renal function recovery, with the aim of providing better preservation solution selection and high-level evidence-based guidance for clinical practice in kidney transplantation.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Descrição detalhada

This is a multicenter, randomized, double-blind, positive-controlled, non-inferiority clinical trial evaluating HCA-N Solution versus Histidine-Tryptophan-Ketoglutarate (HTK) Solution for the preservation of donor kidneys in renal transplantation. HCA-N Solution is a Class III device intended for flushing and preserving isolated kidneys for clinical renal transplantation. Approximately 250 subjects will be enrolled, with 125 subjects in the test group and 125 in the control group, across approximately 20 centers. Donor-recipient pairs must meet the protocol-defined eligibility criteria; eligibility details are provided in the Eligibility Criteria section, and randomization will be 1:1 to the test or control group.

During the screening period (Visit 1 [V1], Day -14 to Day -1 [D-14 to D-1]), potential donors and recipients will be screened for eligibility, informed consent will be obtained, and baseline demographic, medical, immunological, and laboratory information will be collected. The recipient's preoperative baseline estimated glomerular filtration rate (eGFR) value, defined as the last value before transplantation, will be recorded.

On surgery day (Visit 2 [V2], Day 0 [D0]), enrollment and randomization will occur. Vital signs will be recorded, renal transplantation surgery will be performed, and the donor kidney will be flushed and preserved using the assigned preservation solution. Device deficiencies, post-transplant dialysis events, adverse events (AEs), and concomitant treatments will be recorded.

Follow-up visits will occur at Visit 3 (V3, Day 1 [D1]), Visit 4 (V4, Day 3 [D3]), Visit 5 (V5, Day 7 [D7] ± 1), Visit 6 (V6, Day 14 [D14] ± 2), and Visit 7 (V7, Day 28 [D28] ± 3). At these visits, vital signs, laboratory tests including complete blood count, blood biochemistry, and urinalysis, eGFR, dialysis events, adverse events, and concomitant treatments will be recorded. The Day 28 visit will also include physical examination, coagulation function, pregnancy testing for women of childbearing potential, 12-lead electrocardiogram (ECG), and chest computed tomography (CT) or X-ray. Long-term follow-up will collect eGFR, graft survival status, patient survival information, and device-related adverse events.

Efficacy will be assessed primarily by the occurrence of delayed graft function (DGF) after transplantation, with additional renal function parameters within 28 days post-transplantation as specified in the Outcome Measures section. Safety will be evaluated through AEs, serious adverse events (SAEs), vital signs, physical examination, laboratory parameters, ECG, and other protocol-specified assessments.

Statistical analysis will be performed according to prespecified analysis sets. For the primary endpoint, between-group comparisons will use chi-square test, corrected chi-square test, or Fisher's exact test as appropriate, with 95% confidence intervals calculated. Binary secondary endpoints will be analyzed using similar categorical methods. Time-to-event endpoints will be analyzed using the Kaplan-Meier method, including median time, 25%/75% percentiles, 95% confidence intervals, and Kaplan-Meier curves. Continuous eGFR changes from baseline at Days 1, 3, 7, 14, and 28 post-transplantation will be summarized descriptively by group and compared using t-test or rank-sum test as appropriate. Safety analyses will be based on the Safety Set (SS) and will summarize AEs and SAEs by number of events, number of subjects, and incidence rates; AEs will be summarized by severity, System Organ Class (SOC)/Preferred Term (PT), and relationship to the study product. Physical examination, vital signs, 12-lead ECG, and laboratory results will be summarized descriptively.

Tipo de estudo

Intervencional

Inscrição (Estimado)

250

Estágio

  • Fase 2
  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Hubei
      • Wuhan, Hubei, China, 430071
        • Zhongnan Hospital of Wuhan University

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Recipients must meet all of the following criteria:

  • Age 18 to 65 years (inclusive), regardless of gender.
  • Diagnosed as eligible for allogeneic renal transplantation and willing to undergo allogeneic renal transplantation.
  • Understand and agree to comply with the study requirements and voluntarily sign the informed consent form.
  • Require renal transplantation and be first-time transplant recipients.

Donors must meet all of the following criteria:

  • Donor kidney source aged 18 to 65 years (inclusive), regardless of gender.
  • Donor's last serum creatinine before kidney procurement < 2 mg/dL (177 μmol/L), and not having received hemodialysis.

Exclusion Criteria:

Recipients meeting any of the following criteria will be excluded:

  • Planned for dual kidney transplantation.
  • Planned for multi-organ combined transplantation.
  • History of previous organ transplantation.
  • Concurrent severe diseases, such as severe hepatic impairment, cardiopulmonary insufficiency, coagulation disorders, etc.
  • Diagnosis of malignant tumor within 5 years prior to enrollment (except for adequately treated cervical carcinoma in situ, localized cutaneous squamous cell carcinoma, basal cell carcinoma, prostate cancer not requiring antitumor therapy, thyroid cancer, breast ductal carcinoma in situ, and urothelial carcinoma below T1 stage).
  • Panel reactive antibody (PRA) > 10%.
  • Pregnant or lactating women.
  • Participation in other drug or device clinical trials within 3 months prior to enrollment.
  • Donors meeting any of the following criteria will be excluded:
  • Donor has received renal replacement therapy (hemodialysis or continuous renal replacement therapy [CRRT]) prior to screening.
  • Donor has infectious diseases unsuitable for transplantation.

Other requirements:

  • ABO blood group system incompatibility between donor and recipient.
  • Donor kidney warm ischemia time > 10 minutes, or cold ischemia time > 24 hours.
  • Mechanical perfusion preservation required as assessed by the investigator.
  • Other conditions that the investigator deems inappropriate for participation in this trial.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Evaluate the Efficacy and Safety of HCA-N Solution for Preservation of Donor Kidneys

To evaluate the safety and efficacy of HCA-N Solution for the preservation of donor kidneys in renal transplantation, through a comparative study with HTK Solution in kidney organ transplantation.

Experimental Group using HCA-N Solution for the preservation of donor kidneys in renal transplantation

Comparador Falso: comparative with HTK Solution in kidney organ transplantation.

The commonly used methods in clinical practice

control group using HTK Solution in kidney organ transplantation

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of subjects experiencing delayed graft function (DGF) post-transplantation.
Prazo: Baseline at Days 1, 3, 7, 14, and 28 post-transplantation

DGF is defined as the need for dialysis within 1 week after transplantation.

Baseline at Days 1, 3, 7, 14, and 28 post-transplantation

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

5 de dezembro de 2025

Conclusão Primária (Estimado)

9 de abril de 2028

Conclusão do estudo (Estimado)

9 de abril de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

13 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de setembro de 2026

Primeira postagem (Real)

17 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • QD-QGBC-2512

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

The clinical project is underway and the data must be kept confidential.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever